XML 108 R82.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Sep. 26, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Share-based Compensation Expense included in consolidated statements of income          
Share-based compensation expense   $ (72.9) $ (74.1) $ (149.0) $ (153.0)
Subtotal   72.9 76.3 144.3 157.7
Capitalized share-based compensation costs   (2.3) (2.6) (5.6) (5.9)
Share-based compensation expense included in total costs and expenses   70.6 73.7 138.7 151.8
Income tax effect   (13.4) (13.3) (26.3) (28.0)
Selling, General and Administrative Expense   553.8 548.0 1,135.3 1,153.0
Reata Pharmaceuticals, Inc          
Share-based Compensation Expense included in consolidated statements of income          
Operating expenses $ 393.4        
Selling, General and Administrative Expense 196.4        
Research and development expense asset acquired $ 197.0        
Research and development          
Share-based Compensation Expense included in consolidated statements of income          
Share-based compensation expense   27.3 27.9 54.7 59.2
Selling, general and administrative          
Share-based Compensation Expense included in consolidated statements of income          
Share-based compensation expense   45.6 48.4 89.6 98.5
Total share-based compensation expense, net of tax          
Share-based Compensation Expense included in consolidated statements of income          
Share-based compensation expense   $ 57.2 $ 60.4 $ 112.4 $ 123.8